Antibody-drug conjugates (ADCs) consist of monoclonal antibodies (mAbs), cytotoxic payloads, and linkers that link the mAbs and cytotoxic payloads. ADC is a new type of targeted drugs and most ADCs are directed towards oncology indications where the cancer-targeting abilities of specific antibodies are combined with the cancer-killing abilities of cytotoxic payloads to selectively kill cancer cells. It is designed to increase the effectiveness of chemotherapy and reduce its toxicity.